Early Detection of Bone Marrow Involvement in Extramedullary Plasmacytoma by Whole-Body F-18 FDG Positron Emission Tomography

2000 ◽  
Vol 25 (11) ◽  
pp. 870-873 ◽  
Author(s):  
TAKASHI KATO ◽  
ERIKO TSUKAMOTO ◽  
TAKESHI NISHIOKA ◽  
AKIRA YAMAZAKI ◽  
HIROSHI SHIRATO ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Bone Marrow ◽  
Early Detection ◽  
Bone Marrow Involvement ◽  
Extramedullary Plasmacytoma ◽  
Emission Tomography ◽  
Whole Body ◽  
Positron Emission

scholarly journals Positron Emission Tomography (PET) Radiopharmaceuticals in Multiple Myeloma

Molecules ◽  
2019 ◽  
Vol 25 (1) ◽  
pp. 134 ◽  
Author(s):  
Christos Sachpekidis ◽  
Hartmut Goldschmidt ◽  
Antonia Dimitrakopoulou-Strauss
Keyword(s):  
Computed Tomography ◽  
Positron Emission Tomography ◽  
Multiple Myeloma ◽  
Bone Marrow ◽  
Bone Disease ◽  
Emission Tomography ◽  
Whole Body ◽  
Positron Emission ◽  
Pet Ct ◽  
18F Fdg

Multiple myeloma (MM) is a plasma cell disorder, characterized by clonal proliferation of malignant plasma cells in the bone marrow. Bone disease is the most frequent feature and an end-organ defining indicator of MM. In this context, imaging plays a pivotal role in the management of the malignancy. For several decades whole-body X-ray survey (WBXR) has been applied for the diagnosis and staging of bone disease in MM. However, the serious drawbacks of WBXR have led to its gradual replacement from novel imaging modalities, such as computed tomography (CT), magnetic resonance imaging (MRI) and positron emission tomography/computed tomography (PET/CT). PET/CT, with the tracer 18F-fluorodeoxyglucose (18F-FDG), is now considered a powerful diagnostic tool for the detection of medullary and extramedullary disease at the time of diagnosis, a reliable predictor of survival as well as the most robust modality for treatment response evaluation in MM. On the other hand, 18F-FDG carries its own limitations as a radiopharmaceutical, including a rather poor sensitivity for the detection of diffuse bone marrow infiltration, a relatively low specificity, and the lack of widely applied, established criteria for image interpretation. This has led to the development of several alternative PET tracers, some of which with promising results regarding MM detection. The aim of this review article is to outline the major applications of PET/CT with different radiopharmaceuticals in the clinical practice of MM.

scholarly journals Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin’s disease

2003 ◽  
Vol 14 (1) ◽  
pp. 123-130 ◽  
Author(s):  
G. Jerusalem ◽  
Y. Beguin ◽  
M.F. Fassotte ◽  
T. Belhocine ◽  
R. Hustinx ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Early Detection ◽  
Hodgkin's Disease ◽  
Hodgkin’S Disease ◽  
Emission Tomography ◽  
Whole Body ◽  
Positron Emission

scholarly journals Combination bone marrow imaging using positron emission tomography (PET)-MRI in plasma cell dyscrasias: correlation with prognostic laboratory values and clinicopathological diagnosis

BJR|Open ◽  
2019 ◽  
Vol 1 (1) ◽  
pp. 20180020
Author(s):  
Courtney J Tate ◽  
Peter N Mollee ◽  
Kenneth A Miles
Keyword(s):  
Positron Emission Tomography ◽  
Bone Marrow ◽  
Plasma Cell ◽  
Lumbar Vertebrae ◽  
Emission Tomography ◽  
Qualitative Assessment ◽  
Whole Body ◽  
Plasma Cell Dyscrasia ◽  
Water Fraction ◽  
Positron Emission

Objective:This prospective observational study of positron emission tomography (PET)-MRI findings in 16 consecutive newly diagnosed patients with a plasma cell dyscrasia describes and compares MRI-detected myeloma lesions with18F-fludeoxyglucose PET-avid myeloma lesions, and correlates quantitative imaging findings to a range of biochemical and prognostic parameters.Methods:Simultaneously acquired whole body PET and MRI images were evaluated qualitatively for the presence of focal or generalised abnormalities of bone marrow (BM) on either modality. Quantitative analysis comprised mean standardised uptake values (SUVmean) and fractional water content of the BM measured from PET and chemical shift MRI images of the second to fourth lumbar vertebrae.Results:Final diagnoses comprised symptomatic myeloma (n = 10), asymptomatic myeloma (n = 4) and monoclonal gammopathy of uncertain significance (n = 2). 8/10 patients with symptomatic myeloma demonstrated BM abnormalities on qualitative assessment of MRI compared to 4/10 on PET. BM SUVmean inversely correlated with serum albumin (r = 0.57, p = 0.017). BM water fraction correlated with trephine cellularity and blood platelet count (r = 0.78, p = 0.00039 and r = 0.61, p = 0.0013 respectively). BM water fraction correlated with SUVmean in patients with low plasma cell burden (r = 0.91, p = 0.0015) but not in patients with high plasma cell burden (r = 0.18, p = 0.61).Conclusion:PET-MRI shows promise in both morphological and functional multiparametric quantitative assessment of myeloma.Advances in knowledge:For the first time, multiparametric imaging in myeloma has been shown to predict BM abnormalities and correlate with known biochemical prognostic markers, moving PET-MRI beyond simple diagnostic applications into potential prognostic and treatment selection applications.

18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow.

1998 ◽  
Vol 16 (2) ◽  
pp. 603-609 ◽  
Author(s):  
F Moog ◽  
M Bangerter ◽  
J Kotzerke ◽  
A Guhlmann ◽  
N Frickhofen ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Bone Marrow ◽  
Malignant Lymphoma ◽  
Fdg Pet ◽  
Bone Marrow Involvement ◽  
False Negative ◽  
High Rate ◽  
Emission Tomography ◽  
Positron Emission ◽  
Negative Findings

PURPOSE Bone marrow involvement in patients with malignant lymphoma is considered a sign of generalized disease with less favorable prognosis. Bone marrow biopsy (BMB), which represents the standard diagnostic procedure, however, is associated with a high rate of false-negative findings, which may lead to errors in management. The present study was undertaken to investigate the efficacy of positron emission tomography (PET) with 18-F-fluorodeoxyglucose (FDG-PET) as a new method to evaluate bone marrow involvement in patients with malignant lymphoma. METHODS Seventy-eight consecutive, untreated patients with either non-Hodgkin's lymphoma (NHL; n = 39) or Hodgkin's disease (HD; n = 39) were prospectively evaluated. Static FDG-PET imaging was performed following application of 270 MBq (F-18)-FDG. Attenuation correction was performed in 63 of 78 patients. Visual evaluation was performed by two examiners unaware of the clinical data. Material for BMB (70 bilateral, 8 unilateral) was obtained from the posterior iliac crest. Discordant results of PET and biopsy were settled, when possible, on the basis of further biopsy or magnetic resonance imaging (MRI). RESULTS In addition to seven concordant positive and 57 concordant negative findings, biopsy revealed another four cases with bone marrow involvement not detectable by FDG-PET analysis (+5.1%). On the contrary, PET showed bone marrow areas of intensive FDG uptake that suggested bone marrow lymphoma in 10 patients with negative biopsies (+12.8%). In eight patients, FDG-PET findings were confirmed by either histologic verification (n = 4), MRI (n = 2), polymerase chain reaction (PCR) for rearranged immunoglobulin H sequences (n = 1), or clinical presentation (n = 1). Two cases remained unresolved. CONCLUSION The results indicate that FDG-PET has a high potential to detect bone marrow involvement in malignant lymphoma. Besides confirming lesions found at BMB, FDG-PET provided additional information, which, in eight of 78 patients (10.3%), led to an upgrade of the tumor stage.

scholarly journals Fluorine-18 Fluorodeoxyglucose with Positron Emission Tomography Revealed Bone Marrow Involvement in Sarcoidosis Patients with Anaemia

Respiration ◽  
2010 ◽  
Vol 79 (1) ◽  
pp. 25-31 ◽  
Author(s):  
Nicolas de Prost ◽  
Khaldoun Kerrou ◽  
Mathilde Sibony ◽  
Jean-Noël Talbot ◽  
Marie Wislez ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Bone Marrow ◽  
Bone Marrow Involvement ◽  
Emission Tomography ◽  
Positron Emission ◽  
Fluorine 18 Fluorodeoxyglucose
Sign in / Sign up

Export Citation Format

Share Document